Nicolas Villain
LightNews LightNews
banner
nvillain-alz.bsky.social
Nicolas Villain
@nvillain-alz.bsky.social
880 followers 380 following 290 posts
Neurologue Chercheur | Neurologist Researcher | #Alzheimer #Dementia #Neurodegeneration | @fac-sante-sorbonne.bsky.social | @sorbonne-universite.fr | @pitiesalpetriere.bsky.social | @ap-hp.bsky.social | @institutducerveau.bsky.social
Posts Replies Media Videos
Pinned
nvillain-alz.bsky.social
Nicolas Villain @nvillain-alz.bsky.social · Apr 5
Just out in JAMA Neurol blood biomarkers are powerful—but without cognitive phenotyping, we risk more noise than signal.
Plasma p-tau217 needs clinical context or we’ll end up in a false-positive factory!
Clinico-biological AD is a reality!
👉🏻 jamanetwork.com/journals/jam...

bsky.app/profile/vinc...
Reposted by Nicolas Villain
ap-hp.bsky.social
➡️Mise au point de l'AP-HP sur le traitement de la maladie d'Alzheimer par une chirurgie lymphaticoveineuse du cou.
En savoir plus : urlr.me/S87fhs
Traitement de la maladie d’Alzheimer par une chirurgie lympathicoveineuse du cou : l'AP-HP rappelle que cette technique n'est pas validée.
October 31, 2025 at 10:34 AM
nvillain-alz.bsky.social
Chirurgie lymphaticoveineuse du cou et #Alzheimer : rappel de l’ @ap-hp.bsky.social
Technique NON validée, pas de soin hors protocole.
Priorité : essais contrôlés (ANSM, éthique) ; protéger les patients.

bsky.app/profile/ap-h...
ap-hp.bsky.social Assistance Publique – Hôpitaux de Paris (AP-HP) @ap-hp.bsky.social · Oct 31
➡️Mise au point de l'AP-HP sur le traitement de la maladie d'Alzheimer par une chirurgie lymphaticoveineuse du cou.
En savoir plus : urlr.me/S87fhs
Traitement de la maladie d’Alzheimer par une chirurgie lympathicoveineuse du cou : l'AP-HP rappelle que cette technique n'est pas validée.
November 1, 2025 at 3:58 PM
Reposted by Nicolas Villain
lexpress.fr
Médicaments anti-Alzheimer, le débat est nécessaire : l’appel d’un collectif de scientifiques
➡️ https://l.lexpress.fr/r90
October 10, 2025 at 6:48 AM
Reposted by Nicolas Villain
alzheimer-recherche.org
Merci au Dr @nvillain-alz.bsky.social pour sa présentation sur les nouveaux traitements par immunothérapie #alzheimer #traitements.
June 2, 2025 at 12:30 PM
Reposted by Nicolas Villain
europeanjournalofneurology.ean.org
🎉 We’re now on BlueSky!
Follow the European Journal of Neurology 👉 @europeanjournalofneurology.ean.org
Stay up-to-date with the latest in #Neurology!
#MedSky #NeuroSky
May 13, 2025 at 5:04 PM
Reposted by Nicolas Villain
renegadesynapse.bsky.social
Part 1 focused on patient selection challenges. Part 2 will focus on health system readiness. Tara Carlisle and myself were co-first authors on these and benefited greatly from our senior author, Kirk Daffner.
May 7, 2025 at 4:51 PM
Reposted by Nicolas Villain
renegadesynapse.bsky.social
The American Neuropsychiatric Association (No bsky, yet..) dementia special interest group, which I've been the leader of for a number of years, has been working on a two part series for the Journal of Neuropsychiatry and Clinical Neuroscience. Part 1 here.

www.psychiatryonline.org/doi/10.1176/...
Antiamyloid Monoclonal Antibodies in Alzheimer’s Disease, Part 1: Patient Selection | The Journal of Neuropsychiatry and Clinical Neurosciences
The availability of monoclonal antibodies directed against amyloid beta, for use as disease-modifying therapies for Alzheimer’s disease (AD), represented a major shift in the field of AD research and ...
www.psychiatryonline.org
May 7, 2025 at 4:49 PM
Reposted by Nicolas Villain
daniellebeckman.bsky.social
"We call on researchers worldwide to unite and join us ... If you love freedom, come and help us stay free," French President Emmanuel Macron said at Paris' Sorbonne University
#BrainDrain
www.reuters.com/science/eus-...
EU's Von der Leyen announces 500 mln euro package to lure top researchers to Europe
European Commission President Ursula von der Leyen announced on Monday a 500 million euros ($566.6 million) incentive package to boost European science research, as Europe hopes to lure top U.S. scientists disgruntled with President Donald Trump.
www.reuters.com
May 5, 2025 at 6:52 PM
Reposted by Nicolas Villain
alzheimer-recherche.org
RV le 2 juin pour les #EntretiensAlzheimer : avancées de la recherche, nouveaux traitements, prédiction de la maladie… avec @nvillain-alz.bsky.social et #AudreyGabelle Gratuit sur inscription 👉 entretiensalzheimer.org/index.php/il...
May 2, 2025 at 6:11 AM
Reposted by Nicolas Villain
nature.com
Scientists must push back against the threat of rising white nationalism and the dangerous and pseudoscientific ideas of eugenics

https://go.nature.com/42Zryw1
Eugenics is on the rise again: human geneticists must take a stand
Nature - Scientists must push back against the threat of rising white nationalism and the dangerous and pseudoscientific ideas of eugenics.
go.nature.com
April 27, 2025 at 10:01 AM
Reposted by Nicolas Villain
robindeflores.bsky.social
🧠 PhD position available!

Study polypathology in the medial temporal lobe at the Paris Brain Institute with @lemwisse.bsky.social , @nvillain-alz.bsky.social and myself.

This exciting project combines neuroimaging, neuropathology and cognition!

Please share widely 🙏
lemwisse.bsky.social Laura Wisse @lemwisse.bsky.social · Apr 23
Super excited to announce a PhD position on polypathology in the medial temporal lobe at the Paris Brain Institute together with @nvillain-alz.bsky.social and @robindeflores.bsky.social!

offres.institutducerveau-icm.org/fr/jobs/1935...

Please repost!
Nos super offres || PhD - polypathology in the medial temporal lobe
offres.institutducerveau-icm.org
April 24, 2025 at 7:28 AM
nvillain-alz.bsky.social
Exciting opportunity for a PhD position at the @institutducerveau.bsky.social on a European collaborative project under the supervision of medial temporal lobe specialists!
Spread the word!

bsky.app/profile/lemw...
lemwisse.bsky.social Laura Wisse @lemwisse.bsky.social · Apr 23
Super excited to announce a PhD position on polypathology in the medial temporal lobe at the Paris Brain Institute together with @nvillain-alz.bsky.social and @robindeflores.bsky.social!

offres.institutducerveau-icm.org/fr/jobs/1935...

Please repost!
Nos super offres || PhD - polypathology in the medial temporal lobe
offres.institutducerveau-icm.org
April 23, 2025 at 10:26 AM
Reposted by Nicolas Villain
vincentplanche.bsky.social
am pleased to share our letter, highlighting that the science does not yet support regulatory approval of amyloid-targeting therapies for AD based solely on biomarker evidence.
alz-journals.onlinelibrary.wiley.com/doi/full/10....
The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence
Click on the article title to read more.
alz-journals.onlinelibrary.wiley.com
April 17, 2025 at 6:58 PM
Reposted by Nicolas Villain
ansm-gouv.bsky.social
💊Les médicaments contre l’anxiété, c’est pour une courte durée. Ceux contre l’insomnie, c’est pour quelques nuits !

↪️Découvrez notre campagne pour favoriser le #BonUsage des médicaments contre l’anxiété et l’insomnie sévères👉http://lesmedicamentsetmoi.fr

#MedicamentsEtMoi #GCN2025
April 10, 2025 at 7:21 AM
Reposted by Nicolas Villain
dweisman.bsky.social
Great news today. Lecanemab approved in Europe. I quibble with the fact that genetic discrimination is permitted, but this probably won’t last long.
April 15, 2025 at 4:43 PM
nvillain-alz.bsky.social
1/ 🚨 The @ec.europa.eu must now take a stance on lecanemab. After months of delays and an inconclusive Appeal Committee outcome, patients with early Alzheimer’s disease are left in limbo. This has real-world consequences. 🧠🕰️
www.alzheimer-europe.org/news/after-a...
After Appeal Committee “no opinion” on lecanemab for the treatment of Alzheimer’s disease, final decision reverts to European Commission
On 14 April, the minutes of the Appeal Committee of 7 April were published (
www.alzheimer-europe.org
April 14, 2025 at 1:46 PM
nvillain-alz.bsky.social
Just out in JAMA Neurol blood biomarkers are powerful—but without cognitive phenotyping, we risk more noise than signal.
Plasma p-tau217 needs clinical context or we’ll end up in a false-positive factory!
Clinico-biological AD is a reality!
👉🏻 jamanetwork.com/journals/jam...

bsky.app/profile/vinc...
April 5, 2025 at 8:03 AM
Reposted by Nicolas Villain
vincentplanche.bsky.social
Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...
Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers
This cohort study investigates if the clinical phenotype of patients without dementia is associated with blood phosphorylated tau 217 interpretation.
jamanetwork.com
April 4, 2025 at 11:13 AM
Reposted by Nicolas Villain
sorbonne-universite.fr
#VendrediLecture 📚 Un extrême centre s'accrochant au pouvoir sans majorité et faisant alliance avec l’extrême-droite : cette histoire se déroule en Allemagne entre 1930 et 1933.

👉 Avec "Les irresponsables", Johann Chapoutot analyse les conditions de l'arrivée d'Hitler au pouvoir : swll.to/1K1bU8R
Couverture de l'ouvrage.
April 4, 2025 at 7:59 AM
Reposted by Nicolas Villain
alzdemjournals.bsky.social
Recent research published in Alzheimer’s and Dementia investigates plasma phosphorylated tau (p-tau) levels in a diverse cohort.

Results demonstrate differences in plasma p-tau in Black/African American and non-White Hispanic participants.

alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Influence of cognitive impairment and race on plasma p‐Tau217 in two diverse cohorts
INTRODUCTION Factors influencing plasma Alzheimer's disease (AD) biomarkers remain incompletely understood. Here we evaluated Fujirebio plasma p-Tau217 in two diverse cohorts among whom 91% underwen.....
alz-journals.onlinelibrary.wiley.com
March 12, 2025 at 8:45 PM
Reposted by Nicolas Villain
bessfrost.bsky.social
Results from our AntiRetroviral Therapy for Alzheimer's Disease (ART-AD) clinical trial are available online today and will be included in the inaugural issue of npj Dementia.

rdcu.be/edfwq
A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)
npj Dementia - A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)
rdcu.be
March 12, 2025 at 12:49 PM
Reposted by Nicolas Villain
brianpjcronin.bsky.social
Ten years ago if you had written a dystopian SF story in which the person in charge of U.S. public health did a press event at a fast food joint to say that fried food is good but measles vaccines cause measles the ghost of Philip K. Dick would have said that you were being too bleak and unrealistic
atrupar.com Aaron Rupar @atrupar.com · Mar 12
RFK Jr on the measles vaccine: "There are adverse events from the vaccine. It does cause deaths every year. It causes all the illnesses that measles itself cause."
March 12, 2025 at 2:06 AM
Reposted by Nicolas Villain
natrevneurol.nature.com
Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window
INTRODUCTION We assessed the prognostic accuracy of plasma p-tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow-up ...
alz-journals.onlinelibrary.wiley.com
February 27, 2025 at 2:43 PM
Reposted by Nicolas Villain
sfackley.bsky.social
Struggling to compare treatment effects across different cognitive measures?

Check out our new paper.

alz-journals.onlinelibrary.wiley.com/doi/full/10....
Methods to crosswalk between cognitive test scores using data from the Alzheimer's Disease Neuroimaging Cohort
INTRODUCTION Studies use multiple different instruments to measure dementia-related outcomes, making head-to-head comparisons of interventions difficult. METHODS To address this gap, we developed ...
alz-journals.onlinelibrary.wiley.com
February 26, 2025 at 4:54 AM